The repair-deficient subtype showed the most favorable prognosis and may be more responsive to PARP inhibitors, while repair-enhanced and repair-proficient tumors exhibited higher tumor mutation burden (TMB), suggesting potential responsiveness to immunotherapy. This evidence concerns the gene PARP1 and neoplasm.